Female infertility market across 7MM to grow to $2.3 billion by 2033, forecasts GlobalData

03 Jul, 2024 Female infertility market across 7MM to grow to $2.3 billion by 2033, forecasts GlobalData

Posted in Pharma

The female infertility market across the seven major markets (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan) is forecast to increase at a compound annual growth rate (CAGR) of 3.5% from $1.6 billion in 2023 to $2.3 billion in 2033, according to GlobalData, a leading data and analytics company.

GlobalData's latest report, "Female Infertility: Seven Market Drug Forecast and Market Analysis," reveals that this growth during the forecast period will primarily be due to the growing number of women who are postponing pregnancy until later in life when fertility has generally decreases due to age. This will lead to a greater reliance on assisted reproductive technology (ART) fertility treatments, as well as a small growth attributed to the launch of therapies during the forecast period.

Dr Shireen Mohammad, Senior Cardiovascular & Metabolic Disorders Analyst at GlobalData, comments: "A small number of established companies compete in the female infertility market and the market is dominated by off-label therapies, with many drugs used during fertility treatments being indicated for breast cancer and other gynecological disorders, presenting a stiff barrier to the entry of novel therapies. Drugs used to treat female infertility have remained largely unchanged, hence Merck Sereno's, Gonal-F, remains the top selling drug for female infertility with forecasted sales of $713 million by 2033."

The key opinion leaders (KOLs) interviewed by GlobalData described the level of unmet need in this market as moderate. It would be highly desirable to simplify the IVF process by improving the route of administration and dosing frequency of the various drugs involved in the process.

Mohammad continues: "In the fertility market, an easily and less frequently administered drug that performs equally effective to existing options could gain market share. Regarding the use of progesterone for luteal phase support, which patients may be required to take for several weeks or even months at a time, there is a clear need to improve its route of administration to avoid the negative side effects associated with the current intramuscular and vaginal options."

The anticipated launch of IBSA Institute Biochimique's subcutaneous progesterone in the US during the forecast period addresses the unmet need of patient-friendlier progesterone administration in patients undergoing fertility treatments ultimately will improve treatment adherence, satisfaction, and outcomes.

Furthermore, the development of non-injectable fertility medications represents an unmet need. While injectable gonadotropins are commonly used IVF, they require subcutaneous or intramuscular injections, which can be inconvenient, painful, and stressful for patients. Therefore, the development of non-injectable alternatives could offer significant benefits in terms of patient convenience, compliance, and overall treatment experience. This unmet need can be met by the anticipated launch of Kissei Pharmaceutical's oral Gonadotropin-releasing hormone (GnRH) antagonist in the US, France, Spain, and Japan during the forecast period.

Mohammad concludes: "Overall, the female infertility space is set to undergo a moderate increase during the forecast period. KOLs highlighted the female infertility field is evolving but noted that limitations to treatments remain."